17. Business Combinations Description of the Noden Transaction On July 1, 2016, Noden Pharma DAC, entered into an asset purchase agreement (Noden Purchase Agreement) where by it purchased from Novartis the exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna and Tekturna HCT in the United States and Rasilez and Rasilez HCT in the rest of the world (collectively the Noden Products) and certain related assets and assumed certain related liabilities (the Noden Transaction). In addition, pursuant the terms of the Noden Purchase Agreement, Noden Pharma DAC is committed to pay Novartis the following amounts in cash: $89.0 million payable on the first anniversary of the closing date, and up to an additional $95.0 million contingent on achievement of sales targets and the date of the launch of a generic drug containing the pharmaceutical ingredient aliskiren. On July 1, 2016, upon the consummation of the Noden Transaction, a noncontrolling interest holder acquired a 6% equity interest in Noden Pharma DAC and Noden Pharma USA Inc. (together, with any subsidiaries, Noden). The equity interest of the noncontrolling interest holder is subject to vesting and repurchase rights over a four-year period. At March 31, 2017 , 80% of the noncontrolling interest was subject to repurchase. The Company determined that Noden shall be consolidated under the voting interest model as of March 31, 2017 . Pursuant to the Noden Stockholders Agreements, the Company expects to make the following additional equity contributions to Noden: $32.0 million (and up to $89.0 million if Noden is unable to obtain debt financing) on July 1, 2017 to fund the anniversary payment under the Noden Purchase Agreement and at least $38.0 million to fund a portion of certain milestone payments under the Noden Purchase Agreement, subject to the occurrence of such milestones. In connection with the Noden Transaction, Noden Pharma DAC and Novartis also entered into a supply agr